This grant aims to fund the development and validation of targeted mass spectrometric assays crucial for Type 1 Diabetes (T1D) research. Specifically, it seeks highly reproducible and transferable assays for key proteins and peptides like glucagon, C-peptide, insulin, pro-insulin, Glycated CD59, Islet Amyloid Polypeptide (IAPP), Chromogranin A (CgA), and Chromogranin B (CgB). Proposed assays must be validated in human plasma or serum, with an emphasis on ease of transferability to other laboratories. The initiative may also involve creating essential community standards and reference materials where none currently exist, ensuring broad applicability and reliability within the T1D research community.
Opportunity ID: 342298
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DK-21-031 |
| Funding Opportunity Title: | Mass Spectrometric Assays for the Reliable and Reproducible Detection of Proteins/Peptides of Importance in Type 1 Diabetes (T1D) Research (U01 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Food and Nutrition Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.847 — Diabetes, Digestive, and Kidney Diseases Extramural Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jul 14, 2022 |
| Last Updated Date: | Jul 14, 2022 |
| Original Closing Date for Applications: | Oct 26, 2022 |
| Current Closing Date for Applications: | Oct 26, 2022 |
| Archive Date: | Dec 01, 2022 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $700,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | City or township governments Small businesses For profit organizations other than small businesses County governments Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Special district governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing the development and/or validation of targeted mass spectrometric assays (e.g. Multiple Reaction Monitoring) for proteins and peptides of primary interest to the type 1 diabetes research community [e.g. glucagon and other pro-glucagon derived peptides, C-peptide, insulin, pro-insulin, Glycated CD59, Islet Amyloid Polypeptide (IAPP), Chromogranin A (CgA), and chromogranin B (CgB)]. The proposed assays should be highly reproducible, easily transferable to other laboratories, and validated in human plasma or serum. This might also require the development of appropriate community standards, and reference materials when not already available. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-031.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 342298 Full Announcement-RFA-DK-21-031 -> RFA-DK-21-031-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or after January 25, 2022 | PKG00275923 | Sep 26, 2022 | Oct 26, 2022 | View |
Package 1
Mandatory forms
342298 RR_SF424_5_0-5.0.pdf
342298 PHS398_CoverPageSupplement_5_0-5.0.pdf
342298 RR_OtherProjectInfo_1_4-1.4.pdf
342298 PerformanceSite_4_0-4.0.pdf
342298 RR_KeyPersonExpanded_4_0-4.0.pdf
342298 PHS398_ResearchPlan_4_0-4.0.pdf
342298 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
342298 RR_Budget_3_0-3.0.pdf
342298 RR_SubawardBudget30_3_0-3.0.pdf
342298 PHS398_ModularBudget_1_2-1.2.pdf
342298 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
